Sinovac Biotech

Sinovac Biotech Ltd. (Chinese: 北京科兴生物制品有限公司, NASDAQ: SVA) is a biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China.

Sinovac Biotech
Founded1999 (1999)
Headquarters
Beijing
,
China
Websitehttp://www.sinovac.com/
Sinovac Biotech
Simplified Chinese北京科兴生物制品有限公司
Traditional Chinese北京科興生物製品有限公司

Sinovac's commercialized vaccines include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1) and PANFLU.1 (H1N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine.[1]

Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

COVID-19 Vaccine development
See also: COVID-19 vaccine

In mid-April 2020, China approved a clinical trial for a candidate COVID-19 vaccine developed by Sinovac.[2] The vaccine, called CoronaVac, is a chemically-inactivated whole virus vaccine for COVID-19.[3]

In late July 2020, Sinovac began conducting Phase III vaccine trials in Brazil in collaboration with Butantan Institute on 9,000 volunteers, all health professionals, in six Brazilian states.[4] In early August 2020, Sinovac began conducting additional Phase III vaccine trials in Bangladesh with the International Centre for Diarrhoeal Disease Research involving 4,200 volunteers and in Indonesia with Bio Farma in West Java involving 1,600 volunteers.[5][6]

gollark: A-level is hopefully going to be better, since I actually get to pick subjects I like and people who are bad at them won't be doing them.
gollark: Maths is good, though - my maths set has a really good teacher and we do (well, did when school was running) interesting and challenging stuff a lot of the time without repeating the same topic over and over again.
gollark: English is awful because we mostly overanalyze literature and write essays and stuff, but we did writing one time and that was fun.
gollark: A lot of the chemistry and physics stuff we do at school is... somewhat interesting at first, but we end up going over it again and again and doing endless worksheets for some reason, which is not very interesting.
gollark: They might actually be actively negative in some areas, since for quite a lot of people being forced to learn the boring stuff they don't care about will make them ignore the interesting bits.

See also

References
  1. Google Finance, url=https://www.google.com/finance?q=Sinovac
  2. Zhang Zhihao (15 April 2020). "Three COVID-19 vaccines approved for clinical trials". China Daily. Retrieved 23 April 2020.
  3. Nidhi Parekh (22 July 2020). "CoronaVac: A COVID-19 Vaccine Made From Inactivated SARS-CoV-2 Virus". Retrieved 25 July 2020.
  4. Savarese, Mauricio (21 July 2020). "New coronavirus vaccine trials start in Brazil". Associated Press. Retrieved 15 August 2020.
  5. "Bangladesh to host late-stage trial of China's Sinovac COVID-19 vaccine". Reuters. 20 July 2020. Retrieved 15 August 2020.
  6. "Indonesia eyes production of 250 million doses a year of coronavirus vaccine". Reuters. 4 August 2020. Retrieved 15 August 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.